In the current review, we summarise the potential biomarkers for the development of RT and TRT that can be employed in the treatment of BC, including receptor markers of ER, PR and HER2, together with other markers of Trop2, PD‐1, EGFR, GRPR and PSMA. This evidence concerns the gene TACSTD2 and breast cancer.